Last reviewed · How we verify
DESLORELIN
Deslorelin is a small molecule that targets the gonadotropin-releasing hormone receptor. It is used to treat conditions such as precocious puberty and certain types of cancer. The commercial status of deslorelin is patented, with the original developer being Zeneca (now part of AstraZeneca) and the current owner being a subsidiary of Zoetis. Key safety considerations include potential effects on hormone levels and reproductive function. Deslorelin works by binding to the gonadotropin-releasing hormone receptor, which regulates the release of hormones involved in reproductive processes.
At a glance
| Generic name | DESLORELIN |
|---|---|
| Target | Gonadotropin-releasing hormone receptor |
| Modality | Recombinant protein |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia (PHASE3)
- Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease (PHASE2)
- Treatment of Boys With Precocious Puberty (PHASE2)
- Study of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |